Analyst firms · Oppenheimer · ALNY
Oppenheimer ALNY price target and rating history
Alnylam Pharmaceuticals Inc. (ALNY) · Health Care
Oppenheimer rates Alnylam Pharmaceuticals Inc. (ALNY) Outperform with a $500 price target, as of its latest action on Jan 7, 2026. It has published 4 rating actions on ALNY since November 2021, including 2 upgrades and 1 downgrade. Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Oppenheimer's $500 is 54% above that.
- Current rating
- Outperform
- Price target
- $500
- Median target, all firms
- $324
- Actions on ALNY
- 4
Oppenheimer price target on ALNY
Every Oppenheimer rating on ALNY
- Jan 7, 2026
- Aug 4, 2025
- Oct 11, 2023
- Nov 1, 2021
How other firms rate ALNY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Hold | $225 | Nov 2, 2026 |
| Bernstein | Mkt Perform | $199 | Oct 30, 2026 |
| Raymond James | Outperform | $315 | Oct 30, 2026 |
| Stifel | Hold | $225 | Oct 29, 2026 |
| UBS | Buy | $354 | Oct 15, 2026 |
| BMO Capital Markets | Outperform | $318 | Aug 19, 2026 |
| Citigroup | Buy | $380 | May 19, 2026 |
| Jefferies | Hold | $330 | Mar 16, 2026 |
| Barclays | Overweight | $527 | Jan 28, 2026 |
| Oppenheimer | Outperform | $500 | Jan 7, 2026 |
Questions about Oppenheimer and ALNY
- What is Oppenheimer's price target for ALNY?
- Oppenheimer's latest stated price target for Alnylam Pharmaceuticals Inc. (ALNY) is $500, from its action on Jan 7, 2026.
- What is Oppenheimer's rating on ALNY?
- Oppenheimer rates ALNY Outperform, a bullish rating, as of Jan 7, 2026.
- When did Oppenheimer last change its view on ALNY?
- On Jan 7, 2026, Oppenheimer resumes coverage at Outperform, price target $500.
- How does Oppenheimer's ALNY target compare with other analysts?
- Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Oppenheimer's $500 is 54% above that.
More ALNY rating histories
- Raymond James4
- BMO Capital Markets3
- Wolfe Research3
- Goldman Sachs3
- Morgan Stanley8
- Leerink Partners3
- Piper Sandler3
All Oppenheimer ratingsALNY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.